Literature DB >> 28635330

Multiple functions of insulin-degrading enzyme: a metabolic crosslight?

Grazia R Tundo1,2, Diego Sbardella1,2,3, Chiara Ciaccio1,2, Giuseppe Grasso4,5, Magda Gioia1,2, Andrea Coletta6, Fabio Polticelli7, Donato Di Pierro1,2, Danilo Milardi5, Peter Van Endert8, Stefano Marini1,2,3, Massimo Coletta1,2,3.   

Abstract

Insulin-degrading enzyme (IDE) is a ubiquitous zinc peptidase of the inverzincin family, which has been initially discovered as the enzyme responsible for insulin catabolism; therefore, its involvement in the onset of diabetes has been largely investigated. However, further studies on IDE unraveled its ability to degrade several other polypeptides, such as β-amyloid, amylin, and glucagon, envisaging the possible implication of IDE dys-regulation in the "aggregopathies" and, in particular, in neurodegenerative diseases. Over the last decade, a novel scenario on IDE biology has emerged, pointing out a multi-functional role of this enzyme in several basic cellular processes. In particular, latest advances indicate that IDE behaves as a heat shock protein and modulates the ubiquitin-proteasome system, suggesting a major implication in proteins turnover and cell homeostasis. In addition, recent observations have highlighted that the regulation of glucose metabolism by IDE is not merely based on its largely proposed role in the degradation of insulin in vivo. There is increasing evidence that improper IDE function, regulation, or trafficking might contribute to the etiology of metabolic diseases. In addition, the enzymatic activity of IDE is affected by metals levels, thus suggesting a role also in the metal homeostasis (metallostasis), which is thought to be tightly linked to the malfunction of the "quality control" machinery of the cell. Focusing on the physiological role of IDE, we will address a comprehensive vision of the very complex scenario in which IDE takes part, outlining its crucial role in interconnecting several relevant cellular processes.

Entities:  

Keywords:  Alzheimer’s disease; cell homeostasis; heat shock proteins; insulin-degrading enzyme; oxidized proteins turnover; type 2 diabetes; ubiquitin proteasome system

Mesh:

Substances:

Year:  2017        PMID: 28635330     DOI: 10.1080/10409238.2017.1337707

Source DB:  PubMed          Journal:  Crit Rev Biochem Mol Biol        ISSN: 1040-9238            Impact factor:   8.250


  24 in total

1.  Catalytic Mechanism of Amyloid-β Peptide Degradation by Insulin Degrading Enzyme: Insights from Quantum Mechanics and Molecular Mechanics Style Møller-Plesset Second Order Perturbation Theory Calculation.

Authors:  Rui Lai; Wei-Jen Tang; Hui Li
Journal:  J Chem Inf Model       Date:  2018-09-06       Impact factor: 4.956

2.  Liver-specific ablation of insulin-degrading enzyme causes hepatic insulin resistance and glucose intolerance, without affecting insulin clearance in mice.

Authors:  Pablo Villa-Pérez; Beatriz Merino; Cristina M Fernández-Díaz; Pilar Cidad; Carmen D Lobatón; Alfredo Moreno; Harrison T Muturi; Hilda E Ghadieh; Sonia M Najjar; Malcolm A Leissring; Irene Cózar-Castellano; Germán Perdomo
Journal:  Metabolism       Date:  2018-08-08       Impact factor: 8.694

3.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

4.  The insulin-degrading enzyme is an allosteric modulator of the 20S proteasome and a potential competitor of the 19S.

Authors:  Diego Sbardella; Grazia R Tundo; Andrea Coletta; Julien Marcoux; Efthymia Ioanna Koufogeorgou; Chiara Ciaccio; Anna M Santoro; Danilo Milardi; Giuseppe Grasso; Paola Cozza; Marie-Pierre Bousquet-Dubouch; Stefano Marini; Massimo Coletta
Journal:  Cell Mol Life Sci       Date:  2018-03-28       Impact factor: 9.261

5.  New insights into weight management by orlistat in comparison with cinnamon as a natural lipase inhibitor.

Authors:  Naglaa F Khedr; Abla M Ebeid; Rania M Khalil
Journal:  Endocrine       Date:  2019-11-13       Impact factor: 3.633

Review 6.  Inhibition of Insulin Degrading Enzyme to Control Diabetes Mellitus and its Applications on some Other Chronic Disease: a Critical Review.

Authors:  Md Shofiul Azam; Md Wahiduzzaman; Md Reyad-Ul-Ferdous; Md Nahidul Islam; Mukta Roy
Journal:  Pharm Res       Date:  2022-04-04       Impact factor: 4.200

7.  I2-Imidazoline Ligand CR4056 Improves Memory, Increases ApoE Expression and Reduces BBB Leakage in 5xFAD Mice.

Authors:  Bibiana C Mota; Nathan Ashburner; Laura Abelleira-Hervas; Liyueyue Liu; Robertas Aleksynas; Lucio Claudio Rovati; Gianfranco Caselli; Magdalena Sastre
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

Review 8.  Proteases and glycosidases on the surface of exosomes: Newly discovered mechanisms for extracellular remodeling.

Authors:  Ralph D Sanderson; Shyam K Bandari; Israel Vlodavsky
Journal:  Matrix Biol       Date:  2017-10-26       Impact factor: 11.583

9.  Quantitative NMR Study of Insulin-Degrading Enzyme Using Amyloid-β and HIV-1 p6 Elucidates Its Chaperone Activity.

Authors:  Bhargavi Ramaraju; Spencer L Nelson; Wenwei Zheng; Rodolfo Ghirlando; Lalit Deshmukh
Journal:  Biochemistry       Date:  2021-08-03       Impact factor: 3.162

10.  Hydroxypyridinethione Inhibitors of Human Insulin-Degrading Enzyme.

Authors:  Rebecca N Adamek; Caitlin N Suire; Ryjul W Stokes; Monica K Brizuela; Seth M Cohen; Malcolm A Leissring
Journal:  ChemMedChem       Date:  2021-03-31       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.